Arcus Q3 Revenue Falls to $9M; $288M Raise Extends Cash Runway Into 2029
RCUS is trading near its 52-week low of $17.43 (11% above the low).
Summary
Arcus reported Q3 revenue of $9 million versus $26 million a year ago and a $128 million net loss, but with $694 million in cash plus $288 million from its October raise it now has runway into 2029 while it advances casdatifan into first-line Phase 3.
Key Events · Earnings and Guidance · RCUS
-
Q3 Revenue Falls on Gilead Wind-Down
Revenue was $9 million versus $26 million a year ago, driven by lower Gilead collaboration activity; full-year 2026 GAAP revenue is guided to $70-$75 million.
-
Cash Runway Extended Into 2029
$694 million in cash and marketable securities at September 30 plus $288 million gross proceeds from the October equity financing funds planned operations into 2029.
-
Loss Narrows but Stays Large
Net loss was $128 million ($1.00 per share) versus $135 million a year ago; R&D fell to $117 million from $141 million and G&A to $23 million from $27 million.
-
Casdatifan Phase 3 Milestones Ahead
PEAK-1 second-line enrollment is expected complete in the next two to three months, and first-line PEAK-20 is on track to initiate by year-end 2026; more mature PFS/OS data expected in 2027.
Analysis · RCUS · Life Sciences
The balance sheet is the story here: $694 million in cash at quarter end plus $288 million gross from the October equity raise funds operations into 2029, removing near-term financing risk. That runway lets Arcus push casdatifan into first-line Phase 3 with PEAK-20 by year-end and complete PEAK-1 enrollment within two to three months. Revenue, meanwhile, dropped to $9 million from $26 million as Gilead collaboration work winds down, and the company still posted a $128 million quarterly net loss, leaving heavy reliance on casdatifan data in 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RCUS was trading at $19.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $17.43 to $31.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.